Advertisement

Advertisement

2016 ASH Annual Meeting

Advertisement

Advertisement

Apr

24

Today In Oncology

DNA Rearrangement May Predict Treatment Resistance and Poor Outcomes in Multiple Myeloma

Does Squamous Cell Carcinoma Risk Change With Immunosuppression?

Does Oncotype DX–Guided Treatment Reduce Initial Costs of Breast Cancer Care?

Combined Crowd Innovation and AI in Producing Algorithms for Radiotherapy Targeting

Low-Dose Tamoxifen vs Placebo in Preventing Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia

;

Advertisement

Most Read Stories

'Oral Cryotherapy' for Patients Undergoing Oxaliplatin-Based Chemotherapy

Complementary and Alternative Medicine Use in Patients With Cancer

ASCO and ASH Release Update to Clinical Practice Guidelines for Use of Erythropoiesis-Stimulating Agents

Follow-up of Adjuvant Paclitaxel and Trastuzumab in Small HER2-Positive Breast Tumors

KEYNOTE-158: Pembrolizumab in Previously Treated Advanced Cervical Cancer

Most Viewed Videos

Heather A. Wakelee, MD, on Advanced Non–Small Cell Lung Cancer: State-of-the-Art Treatment for EGFR-Positive and ALK-Positive Diseases

Eva M. Ciruelos, MD, PhD, on HER2-Positive Breast Cancer: Results From the PATRICIA Trial

Martin Edelman, MD, on Immunotherapy: How Safe Is It for Patients With Autoimmune Disease?

Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial

Jyoti D. Patel, MD, on Stage III Non–Small Cell Lung Cancer: A Look at New Systemic Treatments

© 2019 HSP News Service, L.L.C.